Where Life Science Scales in Basel

Why It Matters

SONUVO gives biotech and pharma firms immediate access to Basel’s talent pool, infrastructure, and collaborative network, accelerating research timelines and supporting expansion without relocating away from the cluster.

Key Takeaways

• SONUVO offers 35,000 m² lab and office space.
• Located in Allschwil, part of Basel life‑science cluster.
• Buildings originally built for Actelion meet high standards.
• Designed by Herzog & de Meuron, flexible layouts.
• Scalable environment attracts international pharma and biotech firms.

Pulse Analysis

Basel’s life‑science cluster has long been a magnet for global pharmaceutical giants and emerging biotech start‑ups, thanks to its unrivaled talent pipeline, world‑class universities, and a regulatory environment that encourages rapid innovation. The tri‑national location—bordering Switzerland, Germany and France—creates a cross‑border talent pool and facilitates collaborations that span the continent, reinforcing Basel’s reputation as a hub where scientific breakthroughs translate quickly into marketable therapies.

SONUVO’s 35,000 m² of laboratory and office space addresses a critical shortage of flexible, high‑specification facilities in the region. The two‑building campus, originally commissioned by Actelion, adheres to rigorous safety and technical standards, while Herzog & de Meuron’s design blends cutting‑edge lab environments with adaptable office layouts. Building H89 focuses on laboratory infrastructure, enabling advanced assay development and pilot production, whereas G06 offers modern office spaces that support project management, regulatory affairs, and corporate functions. This separation of functions allows companies to scale operations seamlessly as projects progress from discovery to clinical stages.

For companies eyeing growth in Europe, SONUVO provides a strategic foothold within Basel’s ecosystem without the need to construct new facilities from scratch. The ready‑to‑use spaces reduce capital expenditure and accelerate time‑to‑market, while proximity to leading research institutions and multinational pharma partners fosters collaboration and talent acquisition. As the life‑science sector continues to expand, flexible campuses like SONUVO will become essential assets, enabling firms to adapt quickly to evolving scientific and regulatory demands.